↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Träfflista för sökning "WFRF:(Dong YG) "

Search: WFRF:(Dong YG)

Result 1-14 of 14

Sort/group result

Sort by: Hits per page:

Enumeration	Reference	Cover	Find
1.	Jakobsson, J., et al. (author) Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1 2021 In: Autophagy. - : Informa UK Limited. - 1554-8635 .- 1554-8627. ; 17:1, s. 1-382 Journal article (peer-reviewed)
2.	Bittner, VA, et al. (author) Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome 2020 In: Journal of the American College of Cardiology. - : Elsevier BV. - 1558-3597 .- 0735-1097. ; 75:2, s. 133-144 Journal article (peer-reviewed)
3.	Goodman, SG, et al. (author) Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery 2019 In: Journal of the American College of Cardiology. - : Elsevier BV. - 1558-3597 .- 0735-1097. ; 74:9, s. 1177-1186 Journal article (peer-reviewed)
4.	Jukema, JW, et al. (author) Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome: ODYSSEY OUTCOMES Trial 2019 In: Journal of the American College of Cardiology. - : Elsevier BV. - 1558-3597 .- 0735-1097. ; 74:9, s. 1167-1176 Journal article (peer-reviewed)
5.	Ray, KK, et al. (author) Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial 2019 In: The lancet. Diabetes & endocrinology. - 2213-8595 .- 2213-8587. ; 7:8, s. 618-628 Journal article (peer-reviewed)
6.	Roe, MT, et al. (author) Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes 2019 In: Circulation. - : Ovid Technologies (Wolters Kluwer Health). - 1524-4539 .- 0009-7322. ; 140:19, s. 1578-1589 Journal article (peer-reviewed)
7.	Schwartz, GG, et al. (author) Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome 2018 In: The New England journal of medicine. - : MASSACHUSETTS MEDICAL SOC. - 1533-4406 .- 0028-4793. ; 379:22, s. 2097-2107 Journal article (peer-reviewed)
8.	Szarek, M, et al. (author) Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial 2019 In: Circulation. Cardiovascular quality and outcomes. - : Ovid Technologies (Wolters Kluwer Health). - 1941-7705 .- 1941-7713. ; 12:11, s. e005858- Journal article (peer-reviewed)
9.	Szarek, M, et al. (author) Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events: The ODYSSEY OUTCOMES Trial 2019 In: Journal of the American College of Cardiology. - : Elsevier BV. - 1558-3597 .- 0735-1097. ; 73:4, s. 387-396 Journal article (peer-reviewed)
10.	Ahmad, T, et al. (author) Global patient outcomes after elective surgery: prospective cohort study in 27 low-, middle- and high-income countries 2016 In: British journal of anaesthesia. - : Elsevier BV. - 1471-6771 .- 0007-0912. ; 117:5, s. 601- Journal article (peer-reviewed)
11.	Ahmad, T, et al. (author) In-hospital clinical outcomes after upper gastrointestinal surgery: Data from an international observational study 2017 In: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. - : Elsevier BV. - 1532-2157 .- 0748-7983. ; 43:12, s. 2324-2332 Journal article (peer-reviewed)
12.	Ahmad, T, et al. (author) Use of failure-to-rescue to identify international variation in postoperative care in low-, middle- and high-income countries: a 7-day cohort study of elective surgery 2017 In: British journal of anaesthesia. - : Elsevier BV. - 1471-6771 .- 0007-0912. ; 119:2, s. 258-266 Journal article (peer-reviewed)
13.	Jing, X, et al. (author) COVID-19 instigates adipose browning and atrophy through VEGF in small mammals 2022 In: Nature metabolism. - : Springer Science and Business Media LLC. - 2522-5812. ; 4:12, s. 1674- Journal article (peer-reviewed)abstract Patients with COVID-19 frequently manifest adipose atrophy, weight loss and cachexia, which significantly contribute to poor quality of life and mortality1,2. Browning of white adipose tissue and activation of brown adipose tissue are effective processes for energy expenditure3–7; however, mechanistic and functional links between SARS-CoV-2 infection and adipose thermogenesis have not been studied. In this study, we provide experimental evidence that SARS-CoV-2 infection augments adipose browning and non-shivering thermogenesis (NST), which contributes to adipose atrophy and body weight loss. In mouse and hamster models, SARS-CoV-2 infection activates brown adipose tissue and instigates a browning or beige phenotype of white adipose tissues, including augmented NST. This browning phenotype was also observed in post-mortem adipose tissue of four patients who died of COVID-19. Mechanistically, high levels of vascular endothelial growth factor (VEGF) in the adipose tissue induces adipose browning through vasculature–adipocyte interaction. Inhibition of VEGF blocks COVID-19-induced adipose tissue browning and NST and partially prevents infection-induced body weight loss. Our data suggest that the browning of adipose tissues induced by COVID-19 can contribute to adipose tissue atrophy and weight loss observed during infection. Inhibition of VEGF signaling may represent an effective approach for preventing and treating COVID-19-associated weight loss.
14.	Yang, XY, et al. (author) Switching harmful visceral fat to beneficial energy combustion improves metabolic dysfunctions 2017 In: JCI insight. - : American Society for Clinical Investigation. - 2379-3708. ; 2:4, s. e89044- Journal article (peer-reviewed)

Skapa referenser, mejla, bekava och länka

Permalink

Result 1-14 of 14

Refine your search

Type of publication: journal article (14)

Type of content: peer-reviewed (14)

Author/Editor: Das, S. (11); Kumar, P. (11); Li, Y. (9); Zhang, Z. (9); Zhu, H. (9); Kumar, A. (9); show more...; Zheng, Y. (9); King, M. (8); Schmidt, E. (8); Zaman, A. (8); Guo, Y (8); Ahmed, H. (8); Kaiser, S. (8); Nikolaev, K. (8); Schwartz, M. (8); Robinson, S. (8); Costa, F. (8); Diaz, R. (8); Mahajan, A. (8); Davies, R (8); Aggarwal, R. (8); Andersen, K (8); Diaz, A. (8); Cohen, S. (8); Rosenberg, M. (8); Gullestad, L (8); Hong, T. (8); Khan, A. (8); Davis, W. (8); Aboyans, V (8); Khan, M (8); Liu, SW (8); Pandey, A (8); Sarkar, D. (8); Hoffman, D (8); Takahashi, T. (8); Marx, R. (8); Bottcher, M. (8); White, M. (8); Seferovic, P (8); Wells, T (8); Katz, A. (8); Ito, K. (8); Kobayashi-, J (8); Anderson, J. (8); Harding, S (8); Wu, C. (8); Huang, L. (8); Vulic, D (8); Pearce, S (8); show less...

University: Karolinska Institutet (14); Uppsala University (8); Linköping University (2); Lund University (2); Umeå University (1); Stockholm University (1); show more...; Swedish University of Agricultural Sciences (1); show less...

Language: English (14)

Research subject (UKÄ/SCB): Medical and Health Sciences (12); Natural sciences (1)

Year

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

Copyright © LIBRIS - National Library Systems
LIBRIS.kb.se

pil uppåt

Close

Copy and save the link in order to return to this view